Results 151 to 160 of about 125,761 (305)

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

IgG Glycosylation‐Dependent CLEC7A Signaling Drives Podocyte Dysfunction in Lupus Nephritis

Arthritis &Rheumatology, EarlyView.
Objective Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) that can lead to end‐stage kidney disease and increased mortality. IgG from patients with LN displays abnormal glycosylation, contributing to podocyte injury.
Rohit Upadhyay, Alexia Orellana, George C. Tsokos, Rhea Bhargava   +3 more
wiley   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Anti-PS IgG Immune Complexes Impair Macrophage Phagocytosis in SLE via LOX-Dependent Oxidative Stress [PDF]

Hui Guan,1– 3,* Liqi Huang,1,* Yu Liu,1,* Enyi Zhu,4 Lefeng Chen,5 Weijie Li,2 Haiqi Wu,2 Xiaoying Zhang,6 Rencai Qin,2 Jingpeng Zheng,2 Yingqian Mo,5 Ming Zhong,1 Bihua Xu,7 Xiaoyan Dai,8 Qi Wei,2 Yunwei Chen,2 Qingwen Wang,7 ...
Zheng Z, Guan H, Chen L, Tang C, Zhu E, Huang L, Qin R, Wu H, Dai X, Li W, Liu Y, Zheng J, Wang Q, Wei Q, Xu B, Zhang X, Chen Y, Ma K, Mo Y, Zhong M   +19 more
core  

Age‐Associated B Cells Contribute to Inflammation Via Antibody‐Independent Mechanisms in Takayasu Arteritis

Arthritis &Rheumatology, EarlyView.
Objective Although Takayasu arteritis (TAK) is not a prototypical autoantibody‐mediated disease, accumulating evidence suggests that B cells are involved. This study aimed to investigate the pathway of B cell activation and its contributions to TAK pathogenesis. Methods Histologic analysis of paravascular lymph nodes and affected arteries was conducted
Chenglong Fang, Xiaoxi Yang, Xiaochuan Sun, Shangyi Jin, Lihong Du, Jinwei Gao, Jing Li, Zhen Chen, Yuexin Chen, Mengtao Li, Xinping Tian   +10 more
wiley   +1 more source

MicroRNAs in systemic lupus erythematosus: Molecular networks, pathway dysregulation, and therapeutic targeting strategies. [PDF]

Biotechnol Notes
Sadaty MM, Mohamed R, El-Zayat E, Mekhemer SM, El-Ansary A, Mousa NO.   +5 more
europepmc   +1 more source

Type I Interferon Drives Dysfunction of a Distinct CD8+ HLA‐DRB1+ T Cell Subset in Systemic Lupus Erythematosus

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) is characterized by type I interferon (IFN) signaling and adaptive immune dysregulation. We previously identified hypomethylation of HLA‐DRB1 and STAT1 in SLE CD8+ T cells, enabling aberrant IFN‐driven HLA‐DRB1 expression and expansion of a distinct CD8+ T cell subset. This study characterized CD8+ HLA‐DRB1+
Huizhong Long, Elio Carmona, Mikhail G. Dozmorov, Amr H. Sawalha   +3 more
wiley   +1 more source

Single-Cell Transcriptome Reveals the Heterogeneity of T Cells in Mice with Systemic Lupus Erythematosus and Neuronal Inflammation

Journal of Inflammation Research
Zhijie Shi, Haihong Qin, Hao Wu Fudan University, Shanghai, People’s Republic of ChinaCorrespondence: Haihong Qin; Hao Wu, Email tjqhh1982@163.com; seaseewh@163.comIntroduction: Systemic lupus erythematosus is a heterogeneous autoimmune disease.
Shi Z, Qin H, Wu H
doaj  

Development and temporal validation of a clinical prediction model to identify bacterial infection in hospitalised patients with systemic lupus erythematosus. [PDF]

Lupus Sci Med
Wu RQ, Zheng ZX, Zheng QB, Liang HJ, Gong Y, Wang DM, Hou ZD, Lin L.   +7 more
europepmc   +1 more source

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio, Laura A. Cooney, Kohei Maeda, Phillip L. Campbell, Qi Wu, Camila I. Amarista, Alexander Stinson, Ray Ohara, Yang Mao‐Draayer, Michael L. Whitfield, Shiv Pillai, Poulami Dey, Johann E. Gudjonsson, Pei‐Suen Tsou, Dinesh Khanna, David A. Fox   +15 more
wiley   +1 more source